Table 2.
Prognostic factors.
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95%CI) | p-Value | HR (95%CI) | p-Value | |
| Gender (male:female) | 1.071 (0.704–1.634) | 0.747 | ||
| Age, years (<70:≥70) | 1.099 (0.721–1.691) | 0.662 | ||
| Primary tumor site (Ph:Pbt) | 1.019 (0.657–1.559) | 0.929 | ||
| Radiological tumor size, mm (<40:≥40) | 0.911 (0.588–1.392) | 0.669 | ||
| NCCN resectability status of primary tumor (R/BR:UR) | 1.034 (0.673–1.616) | 0.881 | ||
| Peritoneal nodule (−:+) | 0.881 (0.566–1.349) | 0.563 | ||
| Pre-treatment CA19-9, U/mL (<300:≥300) | 0.946 (0.614–1.457) | 0.802 | ||
| Primary treatment (Ctrl:i.p.-PTX) | 0.548 (0.355–0.843) | 0.006 | 0.681 (0.438–1.051) | 0.082 |
| Response (CR/PR:SD/PD) | 0.306 (0.171–0.520) | 0.001 | 0.491 (0.250–0.895) | 0.019 |
| Conversion surgery (−:+) | 0.246 (0.112–0.475) | <0.001 | 0.374 (0.178–0.707) | 0.002 |
Ph, pancreas head; Pbt, pancreas body and tail; NCCN, National Comprehensive Cancer Network; R, resectable; BR, borderline resectable; UR, unresectable; i.p.-PTX, intraperitoneal paclitaxel; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; HR, hazard ratio; CI, confidence interval.